Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 311 for:    Recruiting, Not yet recruiting, Available Studies | Inhibition

Training Inhibition in Alcohol Use Disorder (TRAIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03530384
Recruitment Status : Recruiting
First Posted : May 21, 2018
Last Update Posted : April 29, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
More and more studies aim to improve neurocognitive functioning in alcohol use disorder, but very few studies have focused on training-inhibitory-control efficacy on alcohol intake. Our program relies on a comprehensive model of addiction considering inhibition deficit as the hallmark of addiction. Our program proposes inhibition training on a task which does not refer to alcohol, combined with a debriefing promoting transferability of the enhanced skill and psychoeducation. In this perspective of aiming to retrain deficits involved in addiction in itself and not only due to alcohol toxicity. We propose an add-on single-blinded randomized controlled trial, in alcohol use disorder, assessing the efficacy of a computerized cognitive training program targeting inhibition as compared to treatment as usual.

Condition or disease Intervention/treatment Phase
Alcohol Use Disorder Other: Cognitive training Other: Control training Not Applicable

Detailed Description:

Our hypothesis is that a computerized program aiming to retrain deficits involved in addiction in itself and not only due to alcohol toxicity i.e.inhibition training on tasks which do not refer to alcohol, combined with a debriefing promoting transferability of the enhanced skills, in addition to treatment as usual, is more effective than a control condition in addition to treatment as usual.

The program is a computerized cognitive training targeting inhibitory control of motor response (Scientific Brain Training®). The tasks included in the program have been selected and modified to target inhibition processes. The tasks are "find your way", "Don't fall in the trap", "Under pressure", "gulf-stream", "catch the ladybird" and an additional task: "Color and word Stroop test".

The program must be dispensed twice a week with at least in the week one session on site, the other either on site or at home via an application to download, during 6 weeks.

The duration for one session is 45 minutes, including:

  • 30 minutes performing the selected modules with increasing level of difficulty corresponding to their personal improvement. The patient will be able to choose within the selected modules the ones they want to perform during one session.
  • 15 minutes of group (for onsite sessions) debriefing mediated by a neuropsychologist. The debriefing will follow a semi-structured framework including a focus on the emotion associated with the task completion and a focus on the transferability of the tasks in the patient real life.

Control condition: A sensorial program with similar conditions (45 minutes sessions twice a week), but targeting visual acuity, considered as neutral in the addiction field.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Training Inhibition in Alcohol Use Disorder: an add-on Randomized Controlled Trial
Actual Study Start Date : February 25, 2019
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol

Arm Intervention/treatment
Experimental: Cognitive training
Computerized cognitive training program targeting inhibitory control
Other: Cognitive training
Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks

Sham Comparator: Control Training
A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
Other: Control training
Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks




Primary Outcome Measures :
  1. The reduction in number of heavy drinking days between the last drinking 4-week period and 6 weeks, assessed with the Time Line Follow Back (TLFB). [ Time Frame: 6 weeks ]
    The number of heavy drinking days (HDD) is defined as a day with an alcohol consumption ≥60 g for men and ≥40 g for women.


Secondary Outcome Measures :
  1. Change in total alcohol consumption (g/day) between T1 and - T2, -T3 assessed with the TLFB [ Time Frame: 12 weeks ]
  2. Change in number of heavy drinking days between T1 and -T3 assessed with the TLFB [ Time Frame: 12 weeks ]
  3. Change in Alcohol Quality of life scale between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  4. Change in Clinical Global Impression scale (CGI) severity between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  5. Change in Difficulties in Emotion Regulation Scale-Impulse (DERS-IMPULSE ) between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  6. Change in Stop Signal Reaction Time (SSRT) between T1 and -T2, T3 [ Time Frame: 12 weeks ]
  7. Change in Stop-signal delay (SSD) from the Stop Signal Task (SST) between T1 and -T2, T3 [ Time Frame: 12 weeks ]
  8. Change in Wechsler Adult Intelligence Scale (WAIS) between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  9. Change in Corsi test between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  10. Change in Brixton test between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  11. Change in Trail Making Test (TMT) between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  12. Change in Verbal fluencies test between T1 and -T2, -T3 [ Time Frame: 12 weeks ]
  13. Description of the influence of catechol-O-methyltransferase (COMT) variant on efficacy [ Time Frame: one day ]
    Genotyping of catechol-O-methyltransferase (COMT)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 to 65;
  • With a current alcohol use disorder, according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5), and with at least a high drinking risk level (men: alcohol consumption >60 g/day; women >40 g/day), in the last 4-week drinking period ;
  • Who must be abstinent since 7 to 30 days at the inclusion visit, no matter their drinking goal for the following period ;
  • Who should not have been administered benzodiazepines since at least 3 days at the inclusion visit (to avoid interference with alcohol intoxication or withdrawal medication on the neuropsychological assessments in one hand, and any recall bias on drinking ones in the other hand);
  • Affiliated to social security;
  • Who has given a written informed consent.

Exclusion Criteria:

Will not be included patients:

  • With current alcohol withdrawal symptoms (Cushman score > 3) at the inclusion visit;
  • With dual addiction (excluding tobacco);
  • With psychiatric comorbidity (psychotic disorders, current manic/hypomanic episode, current major depressive episode), as assessed with the Mini International Neuropsychiatric Interview (MINI), Alzheimer disease, Korsakoff syndrome, mental retardation, or any condition that may significantly alter the computerized-task completion, as assessed by the clinician's judgment;
  • Unable or unwilling to comply with the protocol requirements and/or unwilling to sign an informed consent form.
  • Deprived of liberty or under legal protection measure.
  • Pregnant or lactating woman

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03530384


Contacts
Layout table for location contacts
Contact: Amandine LUQUIENS, Dr 01 45 59 30 87 amandine.luquiens@aphp.fr

Locations
Layout table for location information
France
Paul Brousse Hospital Recruiting
Villejuif, France, 94800
Contact: Amandine LUQIENS, Dr    01 45 59 30 87    amandine.luquiens@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03530384     History of Changes
Other Study ID Numbers: P160930J
2017-A03558-45 ( Other Identifier: ANSM )
First Posted: May 21, 2018    Key Record Dates
Last Update Posted: April 29, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Alcoholism
Alcohol Drinking
Pathologic Processes
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders